Clinical trial
A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients With Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens
NCT02354586 is registered in ClinicalTrials.gov with Tesaro, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients With Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens
- Lead sponsor
- Tesaro, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 23, 2015
- Completion date
- August 23, 2021
- Enrollment
- 463 (actual)
- Sites
- 55
Conditions
As the registry lists them; a condition with its own page is linked.
ovarian cancer, ovarian neoplasms